Yarrow Bioscience (YARW) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
13 Nov, 2026Executive summary
YB-101 is an anti-TSHR antibody for Graves’ disease (GD) and thyroid eye disease (TED); the DIRECTION-GD Phase 2a/2b trial is underway, with Phase 2a topline results expected in H2 2027.
FDA cleared the GD investigational new drug application in March 2026 and granted Fast Track designation on May 20, 2026.
The first patient has been dosed in the randomized, blinded, placebo-controlled Phase 2a trial; enrollment is ongoing.
Financial highlights
Q3 2026 R&D and G&A expenses were $5.3M and $5.5M; operating loss was $10.7M and net loss was $9.7M.
For 9M 2026, R&D and G&A expenses were $11.5M and $8.8M; operating loss was $20.3M and net loss was $19.0M.
Other income, primarily interest, was $1.0M in Q3 and $1.3M for 9M 2026; no comparative 2025 periods are presented.
Outlook and guidance
Cash at September 30, 2026 is expected to fund operations into 2030, including DIRECTION-GD and preparation for a planned TED study; the estimate depends on assumptions that may change.
DIRECTION-GD Phase 2a topline results are expected in H2 2027; the trial evaluates safety, PK, PD and efficacy through 24 weeks.
Phase 2b is expected to begin enrolling in H1 2028 as a dose-finding study of ~200 patients, with dose selection informed by Phase 2a data.
GenSci’s Phase 1 TED multiple-ascending-dose data are expected in H2 2027 and to inform global TED development plans.
R&D costs are expected to rise as YB-101 advances; G&A is expected to increase with headcount, public-company costs and IP activity.
Latest events from Yarrow Bioscience
- YB-101 targets TSHR across GD and TED, with key clinical data expected in 2027.YARW
Investor presentation - YB-101 advances dual-indication TSHR blockade, with key data expected in 2H 2027.YARW
3rd Annual Guggenheim Healthcare Innovation Conference - Merger completed, $200M raised, YB-101 trial advanced, and Q2 net loss was $6.5M.YARW
Q2 2026 - YB-101 targets unmet needs in GD and TED with a novel, well-funded, and differentiated approach.YARW
Investor presentation - Advancing BET inhibitors for autoimmune diseases with robust trials and strong financial runway.YARW
Stifel 2024 Immunology and Inflammation Virtual Summit - Net loss narrowed 58% year-over-year as R&D spending dropped ahead of the Yarrow merger.YARW
Q1 2026 - Losses narrowed in 2025 as the company pivots to a merger with Yarrow and exits key R&D programs.YARW
Q4 2025 - BET inhibitor programs advance in vitiligo and psoriasis, with key clinical readouts expected in 2024.YARW
H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - BET inhibitor programs advance in vitiligo and psoriasis, with pivotal data expected in 2024–2025.YARW
TD Cowen 45th Annual Healthcare Conference